Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

IMPORTANCE: To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report the results of t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Ophthalmol
Autores principales: Gillies, Mark C., Hunyor, Alex P., Arnold, Jennifer J., Guymer, Robyn H., Wolf, Sebastian, Ng, Paul, Pecheur, Francois L., McAllister, Ian L.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459213/
https://ncbi.nlm.nih.gov/pubmed/30676617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaophthalmol.2018.6776
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares